Benitec Biopharma Inc.
↗Hayward, California, USA
Benitec Biopharma Inc. is a clinical-stage biotechnology company developing novel genetic medicines using its proprietary DNA-directed RNA interference (ddRNAi) technology platform. The company combines the power of RNA interference with the durability of expression from gene therapy delivery to permanently silence disease-causing genes. Founded in Australia in 1997, Benitec is now a public company traded on NASDAQ (BNTC) and the ASX (BLT), with its US headquarters in Hayward, California. The company focuses on rare genetic disorders, with its lead program BB-301 in Phase 1b/2a clinical trials for oculopharyngeal muscular dystrophy (OPMD), and preclinical programs in hepatitis B and other genetic diseases.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Gene Therapy, Genetic Medicine
SIZE & FINANCIALS
Employees:11-50
Revenue:$0 (clinical-stage, pre-commercialization)
Founded:1997
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO (Public Company)
Total Raised:$100M+
Investors:Suvretta Capital, NantCapital LLC (19.99% stake as of strategic investment)
STOCK
Exchange:NASDAQ
Ticker:BNTC
Market Cap:$456M
PIPELINE
Stage:Phase 1b/2a (BB-301), Preclinical (other programs)
Lead Drug Stage:Phase 1b/2a
Modalities:Gene Therapy, RNA Interference (RNAi), AAV vector-based therapy
Active Trials:1
Trial Phases:Phase 1: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Benitec Biopharma Limited (Australian parent company)
Subsidiaries:Benitec Biopharma Inc. (US)
Key Partnerships:Axovant Sciences (BB-301 licensing partner), NantCapital/NantWorks (collaboration for head and neck cancer programs, 19.99% strategic stake), CSIRO (exclusive license to ddRNAi technology in human therapeutics), Novartis (partnership), National Institutes of Health (NIH) (partnerships)
COMPETITION
Position:Challenger - Only clinical-stage therapeutic in development for OPMD; first-mover advantage in this indication
Competitors:BridgeBio Pharma, Spark Therapeutics, Exact Sciences, Other AAV and gene therapy developers (Ultragenyx, Sesen Bio, Regenxbio)
LEADERSHIP
Key Executives:
Dr. Jerel Banks, M.D., Ph.D. - Chief Executive Officer & Chairman
Megan Boston - Executive Director
Edward Smith - Board Member (Director since April 2020)
Dr. Sharon Mates, Ph.D. - Board Member (Appointed November 2025)
Sophie Mukadam - Associate Director, Program Management
Board Members:Dr. Jerel Banks (Chairman & CEO), Megan Boston (Executive Director), Dr. Sharon Mates (Director, appointed Nov 2025), Edward Smith (Director, since April 2020), Additional board members not fully disclosed in public records
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Benitec Biopharma Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Benitec Biopharma Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.